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Background: Although infections with multiple HPV types
ave been readily reported, more information is needed for
ccurrence of the different types at individual or at the
opulation level, e.g., across countries Objective: We deter-
ined the distribution of seroprevalences to multiple HPV
ypes in Finland and Uganda to compare epidemiology of the
ifferent HPV types in the two populations.
Methods: Cross-sectional seroprevalence study of ante-
atal clinic attendants. In Finland serum samples were
andomly drawn from a subset of samples collected between
995 -2007 for the Finnish Maternity cohort and in Uganda,
amples were collected (between 2004-2008) from women
nrolled after consenting. The serum samples were stored
nd analysed for HPV antibodies against seven HPV types; 6,
1, 16, 18, 31, 33, and 45 using direct VLP ELISA.
Results: Sera were analysed for 2 784 Finnish and 1 964
gandan women (mean ages 22 and 25 years) of whom 44%
nd 57% had antibodies to at least one of the seven HPV
ypes (6/11/16/18/31/33/45) tested (p < 0.001). Multiple
PV antibody positivity was common. Finnish women, who
ere HPV45 seropositive (F-HPV45), had higher adjusted
isk estimates of having antibodies to most of the other
PV types (HPV18, 31 and 33) than comparable Ugan-
an women (U-HPV45): F-HPV45:HPV18 (OR = 10.9, 95% CI
.3-23) vs. U-HPV45:HPV18 (OR = 3.4, 95% CI 2.3-5.0), F-
PV45:HPV31 (OR = 6.1, 95% CI 2.8-13.4) vs. U-HPV45:HPV31
OR= 2.2, 95% CI 1.6-3.0), and F-HPV45:HPV33 (OR = 12.2,
5% CI 5.8-26) vs. U-HPV45:HPV33 (OR = 3.3, 95% CI 2.4-
.5). This was true also for antibodies to HPV31 and HPV33
mong HPV18 seropositive Finnish women (F-HPV18) vs.
PV18 seropositive Ugandan women (U-HPV18) albeit with
omewhat overlapping conﬁdence intervals: F-HPV18:HPV31
OR= 5.2, 95% CI 3.0-9.0) vs. U-HPV18:HPV31 (OR = 3.1, 95%
I 2.2-4.4), F-HPV18:HPV33 (OR = 6.9, 95% CI 4.1-11.7) vs. U-
PV18:HPV33 (OR = 3.3, 95% CI 2.3-4.6). In general, among
he HPV16 seropositives increased risk estimates for being
eropositive for a second HPV type were observed but major
ifferences were not observed between the Finns and the
gandans.
Conclusion: We observed remarkably increased risk esti-
ates for being double HPV antibody positive among HPV45
nd HPV18 seropositive Finns as compared to the Ugandans.
n conclusion, biological, behavioral factors, iatrogenic and
ocietal factors (screening vs no screening) may result in
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he different occurrence of infections with the high risk HPV
ypes in Finland and Uganda.
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Background: Achieving rapid protection against hepatitis
can be critical for travellers. HBsAg-ISS (HEPLISAVTM) is an
nvestigational vaccine containing Hepatitis B surface anti-
en (HBsAg) and 1018 Immunostimulatory Sequence (ISS), a
oll-like Receptor 9 (TLR9) agonist adjuvant. A Phase 3 study
f subjects 18-55 years of age demonstrated non-inferiority
f a short, 2 dose regimen of HBsAg-ISS to a 3 dose reg-
men of a licensed vaccine. This analysis in subjects >40
ears of age compares the seroprotection rate (SPR), mea-
ured by antibody to HBsAg [anti-HBsAg] ≥10mIU/mL, and
nti-HBsAg geometric mean concentration (GMC) of HBsAg-
SS with licensed vaccine (Engerix-B, 20 mcg). This study
emonstrated that the SPR of a short, 2 dose regimen of
BsAg-ISS in subjects 18-55 and in subjects over 40 is supe-
ior to the standard regimen of Engerix-B. This vaccine could
rovide a better solution for clinicians needing rapid, safe
nd effective protection against hepatitis B disease for trav-
lers.
Methods: A randomized observer-blind study comparing
doses of HBsAg-ISS at months 0 and 1 with saline placebo
t month 6 to 3 doses of licensed vaccine at months 0, 1,
nd 6. Anti-HBsAg were measured at months 0, 1, 2, 3, 6,
nd 7. Safety, including local and systemic reactogenicity
nd adverse events was assessed.
Results: 2101 subjects, including 1188 subjects over age
0, were included in the per-protocol analysis in a 3:1 ran-
omization of HBsAg-ISS to Engerix-B. The primary endpoint
PR for all subjects was statistically signiﬁcantly higher for
BsAg-ISS (95% at month 3) vs. Engerix-B (81% at month
) [p < 0.0001]. For subjects over age 40 the primary end-
oint SPR was 92% for HBsAg-ISS and 75% for Engerix-B)
p < 0.0001]; the GMC (mIU/mL) at month 7 was 236 for
BsAg-ISS and 218 for Engerix-B. HBsAg-ISS was safe, well-
olerated and comparable to Engerix-B with regard to local
nd systemic adverse events and serious adverse events. Two
ases of ANCA-associated vasculitis were observed; one in an
BsAg-ISS subject and one in an Engerix-B subject. A review
f AEs potentially associated with autoimmune conditions
evealed no difference between groups.
Conclusion: This study demonstrated that the SPR of a
hort, 2 dose regimen of HBsAg-ISS in subjects 18-55 and
n subjects over 40 is superior to the standard regimen of
ngerix-B. This vaccine could provide a better solution for
linicians needing rapid and safe protection against hepatitis
disease for travelers.
oi:10.1016/j.ijid.2010.02.1881
